News & Updates
Breakthroughs from the Field
The results of the RADIANT4 trial by Dr James C. Yao, chair of the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, are in. … read more
Study Shows PRRT Treatment Significantly Increased Progression-Free Survival for Advanced Midgut NETs
The results from the first large scale randomized control trial of Peptide Receptor Radionuclide Therapy (PRRT) were released last week at the European Cancer Congress 2015 meeting in Vienna, Austria. The data … read more
Lexicon Pharmaceuticals Reports Positive Top-Line Results for Pivotal Phase 3 Telotristat Etiprate Study in Cancer Patients with Carcinoid Syndrome
(From the Lexicon website) Lexicon Pharmaceuticals, Inc. announced that the pivotal TELESTAR Phase III clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients … read more
NET Research Foundation Launches Major Immunotherapy Initiative
A treatment that uses the body’s own immune system to fight cancer, immunotherapy has led to dramatic results for some patients with other forms of cancer. We are eager to test the potential of immune-based therapy to provide similar breakthroughs for patients with neuroendocrine cancers.
Thank you for your Generous Donation!
Your support enables the NET Research Foundation to make rapid progress toward discovering cures for carcinoid, pancreatic, and related neuroendocrine cancers.